FDA Accepts Recros Medica De Novo Submission for Nuvellus Focal Contouring System
Recros Medica, Inc. announced today that its de novo regulatory submission for the Nuvellus™ Focal Contouring System has been accepted for review by the US Food and Drug Administration (FDA). Nuvellus™, which utilizes the company’s proprietary Rotational Fractional Resection (RFR) technology, may provide medical aesthetic physicians a minimally-invasive single treatment option to improve submental (neck and jowl) contouring.
A First Look at Rotational Fractional Resection
A new technology offers a fresh approach to treatment of submental contouring.
Rotational Fractional Resection Hits the Sweet Spot for a More Defined Neckline
The Nuvellus Focal Contouring System, incorporating the Rotational Fractional Resection (RFR) technology in development by Recros Medica Inc, may fill that gap.
Dermatology Times – Oct. 2018
A promising new minimally invasive procedure for skin contouring.
CONFORM Clinical trial poster
Efficacy, Safety, and Subject Satisfaction Using Rotational Fractional Resection for the Improvement of Submental Contouring. By Steve Dayan, MD; Jill Waibel, MD; Steve Yoelin, MD CONFORM clinical trial poster
Recros Medica Showcases Interim Data on Rotational Fractional Resection Technology at 2018 ASDS
SAN DIEGO, Oct. 9, 2018 /PRNewswire/ -- Recros Medica, Inc. announced today it will showcase its Rotational Fractional Resection (RFR) platform at the 2018 American Society for Dermatologic Surgery Annual Meeting. This investigational technology which is being developed as the Nuvellus™ Focal Contouring System for use by dermatologists, plastic surgeons and other aesthetic physicians to reduce skin laxity and remove Read more